Skip to main content
Premium Trial:

Request an Annual Quote

Microchip Biotechnologies Licenses GE Microfluidics Patents

NEW YORK (GenomeWeb News) – Microchip Biotechnologies said today that it has licensed certain patents from General Electric’s GE Healthcare division that cover design and methods for creating integrated fluidic microchip devices.
MBI said the license would “significantly enhance” its intellectual property portfolio supporting development of lab-on-a-chip devices. The Dublin, Calif.-based firm said that it would use the licensed technology to develop and market "sample-to-answer" systems for genomic analyses and molecular diagnostics.
"Microfluidic devices will play a critical role in next-generation instrumentation that delivers fully automated, cost-effective bioassay solutions in the life sciences, applied sciences, and molecular diagnostics,” said Stevan Jovanovich, president and CEO of MBI, in a statement.
Financial terms of the alliance were not disclosed.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.